Charles Schwab’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Charles Schwab’s Portfolio HTGM Stock Details HTGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-104	Closed	-$7K	–	3417
2020 Q3	$7K	Hold	104	–	–	﹤0.01%	3341
2020 Q2	$14K	Hold	104	–	–	﹤0.01%	3308
2020 Q1	$7K	Hold	104	–	–	﹤0.01%	3226
2019 Q4	$14K	Hold	104	–	–	﹤0.01%	3167
2019 Q3	$13K	Hold	104	–	–	﹤0.01%	3169
2019 Q2	$31K	Hold	104	–	–	﹤0.01%	3184
2019 Q1	$47K	Buy	+104	New	+$45.5K	﹤0.01%	3144

Other funds holding HTGM

CPA

Cowen Prime Advisors New York $290M AUM 57.8% 1-Year Est. Return

Samjo Capital New York $254M AUM 36.81% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Charles Schwab's HTGM Position: Q4 2020 in Review

Charles Schwab sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q4 2020, closing a stake of 104 shares — an estimated $7K sold.

Charles Schwab first reported a position in HTGM in Q1 2019 and held it in 7 quarters. The position peaked at $47K in Q1 2019. 23 funds tracked by Wall St. Rank hold HTGM as of Q4 2020.

Charles Schwab reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
Charles Schwab sold 104 HTG Molecular Diagnostics, Inc. Common Stock shares in Q4 2020, an estimated $7K.
Charles Schwab first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q1 2019 and held it in 7 quarters.
Charles Schwab's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $47K in Q1 2019.
23 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q4 2020.

Based on Charles Schwab's 13F filing for Q4 2020, filed 16 Feb 2021.